Physiology and pharmacology of the prostaglandin J2 family

Yoshikazu Miwa, Yoji Taba, Megumi Miyagi, Toshiyuki Sasaguri

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The prostaglandin (PG) J2 family including PGJ2, Δ12-PGJ2, and 15-deoxy-Δ 12,14-PGJ2 (15d-PGJ2) are metabolites of PGD2. They had been known as powerful inhibitors of cell proliferation and viral replication until 15d-PGJ2 was found to be a natural ligand for peroxisome proliferator-activated receptor γ (PPARγ). Since then, several new pharmacological actions of the PGJ 2 family have been found, such as pro- and anti-apoptotic effects, cell differentiation-inducing effects, and inhibitory effects on inflammatory processes, whether they depend on PPARγ or not. We reported that the PGJ2 family, particularly 15d-PGJ2, inhibits cell proliferation by reducing the expression of G1 cyclins and inducing the expression of cyclin-dependent kinase inhibitor p21 and moreover, induces cell differentiation in vascular smooth muscle cells. In vascular endothelial cells, we found that 15d-PGJ2 inhibits apoptotic cell death at least in part by the induction of the inhibitor of apoptosis protein c-IAP1. More importantly, physiological levels of laminar fluid shear stress loaded on endothelial cells upregulate the expression of lipocalin-type PGD2 synthase, which converts PGH2 to PGD2, the precursor of the PGJ2 family. Based on these results, we have hypothesized that the PGJ2 family synthesized in vascular wall plays an important physiological role to protect vascular cells from atherogenic stimuli.

Original languageEnglish
Pages (from-to)34-40
Number of pages7
JournalFolia Pharmacologica Japonica
Volume123
Issue number1
DOIs
Publication statusPublished - Feb 10 2004

Fingerprint

Pharmacology
Prostaglandin D2
Peroxisome Proliferator-Activated Receptors
prostaglandin R2 D-isomerase
Blood Vessels
Cell Differentiation
Endothelial Cells
Cyclin G1
Cell Proliferation
9-deoxy-delta-9-prostaglandin D2
Prostaglandin H2
Cyclin-Dependent Kinase Inhibitor p21
Inhibitor of Apoptosis Proteins
Lipocalins
Vascular Smooth Muscle
Smooth Muscle Myocytes
Cell Death
Up-Regulation
Ligands

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Physiology and pharmacology of the prostaglandin J2 family. / Miwa, Yoshikazu; Taba, Yoji; Miyagi, Megumi; Sasaguri, Toshiyuki.

In: Folia Pharmacologica Japonica, Vol. 123, No. 1, 10.02.2004, p. 34-40.

Research output: Contribution to journalArticle

Miwa, Yoshikazu ; Taba, Yoji ; Miyagi, Megumi ; Sasaguri, Toshiyuki. / Physiology and pharmacology of the prostaglandin J2 family. In: Folia Pharmacologica Japonica. 2004 ; Vol. 123, No. 1. pp. 34-40.
@article{2098a045cf8343beb76685bd9fe5362c,
title = "Physiology and pharmacology of the prostaglandin J2 family",
abstract = "The prostaglandin (PG) J2 family including PGJ2, Δ12-PGJ2, and 15-deoxy-Δ 12,14-PGJ2 (15d-PGJ2) are metabolites of PGD2. They had been known as powerful inhibitors of cell proliferation and viral replication until 15d-PGJ2 was found to be a natural ligand for peroxisome proliferator-activated receptor γ (PPARγ). Since then, several new pharmacological actions of the PGJ 2 family have been found, such as pro- and anti-apoptotic effects, cell differentiation-inducing effects, and inhibitory effects on inflammatory processes, whether they depend on PPARγ or not. We reported that the PGJ2 family, particularly 15d-PGJ2, inhibits cell proliferation by reducing the expression of G1 cyclins and inducing the expression of cyclin-dependent kinase inhibitor p21 and moreover, induces cell differentiation in vascular smooth muscle cells. In vascular endothelial cells, we found that 15d-PGJ2 inhibits apoptotic cell death at least in part by the induction of the inhibitor of apoptosis protein c-IAP1. More importantly, physiological levels of laminar fluid shear stress loaded on endothelial cells upregulate the expression of lipocalin-type PGD2 synthase, which converts PGH2 to PGD2, the precursor of the PGJ2 family. Based on these results, we have hypothesized that the PGJ2 family synthesized in vascular wall plays an important physiological role to protect vascular cells from atherogenic stimuli.",
author = "Yoshikazu Miwa and Yoji Taba and Megumi Miyagi and Toshiyuki Sasaguri",
year = "2004",
month = "2",
day = "10",
doi = "10.1254/fpj.123.34",
language = "English",
volume = "123",
pages = "34--40",
journal = "Folia Pharmacologica Japonica",
issn = "0015-5691",
publisher = "Japanese Pharmacological Society",
number = "1",

}

TY - JOUR

T1 - Physiology and pharmacology of the prostaglandin J2 family

AU - Miwa, Yoshikazu

AU - Taba, Yoji

AU - Miyagi, Megumi

AU - Sasaguri, Toshiyuki

PY - 2004/2/10

Y1 - 2004/2/10

N2 - The prostaglandin (PG) J2 family including PGJ2, Δ12-PGJ2, and 15-deoxy-Δ 12,14-PGJ2 (15d-PGJ2) are metabolites of PGD2. They had been known as powerful inhibitors of cell proliferation and viral replication until 15d-PGJ2 was found to be a natural ligand for peroxisome proliferator-activated receptor γ (PPARγ). Since then, several new pharmacological actions of the PGJ 2 family have been found, such as pro- and anti-apoptotic effects, cell differentiation-inducing effects, and inhibitory effects on inflammatory processes, whether they depend on PPARγ or not. We reported that the PGJ2 family, particularly 15d-PGJ2, inhibits cell proliferation by reducing the expression of G1 cyclins and inducing the expression of cyclin-dependent kinase inhibitor p21 and moreover, induces cell differentiation in vascular smooth muscle cells. In vascular endothelial cells, we found that 15d-PGJ2 inhibits apoptotic cell death at least in part by the induction of the inhibitor of apoptosis protein c-IAP1. More importantly, physiological levels of laminar fluid shear stress loaded on endothelial cells upregulate the expression of lipocalin-type PGD2 synthase, which converts PGH2 to PGD2, the precursor of the PGJ2 family. Based on these results, we have hypothesized that the PGJ2 family synthesized in vascular wall plays an important physiological role to protect vascular cells from atherogenic stimuli.

AB - The prostaglandin (PG) J2 family including PGJ2, Δ12-PGJ2, and 15-deoxy-Δ 12,14-PGJ2 (15d-PGJ2) are metabolites of PGD2. They had been known as powerful inhibitors of cell proliferation and viral replication until 15d-PGJ2 was found to be a natural ligand for peroxisome proliferator-activated receptor γ (PPARγ). Since then, several new pharmacological actions of the PGJ 2 family have been found, such as pro- and anti-apoptotic effects, cell differentiation-inducing effects, and inhibitory effects on inflammatory processes, whether they depend on PPARγ or not. We reported that the PGJ2 family, particularly 15d-PGJ2, inhibits cell proliferation by reducing the expression of G1 cyclins and inducing the expression of cyclin-dependent kinase inhibitor p21 and moreover, induces cell differentiation in vascular smooth muscle cells. In vascular endothelial cells, we found that 15d-PGJ2 inhibits apoptotic cell death at least in part by the induction of the inhibitor of apoptosis protein c-IAP1. More importantly, physiological levels of laminar fluid shear stress loaded on endothelial cells upregulate the expression of lipocalin-type PGD2 synthase, which converts PGH2 to PGD2, the precursor of the PGJ2 family. Based on these results, we have hypothesized that the PGJ2 family synthesized in vascular wall plays an important physiological role to protect vascular cells from atherogenic stimuli.

UR - http://www.scopus.com/inward/record.url?scp=0742305938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0742305938&partnerID=8YFLogxK

U2 - 10.1254/fpj.123.34

DO - 10.1254/fpj.123.34

M3 - Article

C2 - 14695456

AN - SCOPUS:0742305938

VL - 123

SP - 34

EP - 40

JO - Folia Pharmacologica Japonica

JF - Folia Pharmacologica Japonica

SN - 0015-5691

IS - 1

ER -